Summary
Guggenheim analyst Yatin Suneja has identified Surrozen Inc (NASDAQ: SRZN) as his pick within the biotechnology sector based on recent regulatory and clinical developments centered on eye disease therapies. Key elements include an Investigational New Drug application for SZN-8141, a financing milestone tied to IND clearance, and a projected clinical timeline that stretches into 2026. The broader ophthalmology field is also watching Merck’s BRUNELLO study results, which are scheduled for presentation in October 2026.
Key points
- Surrozen submitted an IND for SZN-8141, a bispecific candidate that combines Wnt agonism with an anti-VEGF component to treat diabetic macular edema.
- According to Guggenheim, clearance of this IND triggers the second tranche of $98.4 million from Surrozen’s 2025 financing round, which totals $175 million, providing support for upcoming clinical programs.
- Surrozen is expected to begin the Phase Ib/IIa DUET study in diabetic macular edema patients by the end of 2026, with initial Phase Ib single ascending dose data and a potential interim look into Phase IIa to follow.
Details of the IND and financing
Surrozen has filed an IND for SZN-8141, described as a bispecific therapy pairing Wnt pathway agonism with an anti-VEGF element, aimed at treating diabetic macular edema. Guggenheim states that successful clearance of this application will activate the second tranche of $98.4 million from the company’s $175 million financing round completed in 2025. Guggenheim expects a smooth IND clearance process over the next 30 days.
The financing tied to the IND is expected to underwrite Surrozen’s activities through the Phase Ib/IIa DUET study for SZN-8141 and to support a separate Phase I safety, tolerability, and efficacy trial for SZN-8143. That latter candidate is described as combining activity at FZD4 and LRP5/6 together with anti-VEGF and anti-IL-6 properties.
Clinical timeline and sector context
Guggenheim indicates Surrozen remains on track to initiate the Phase Ib/IIa DUET study in diabetic macular edema patients by the end of 2026. The firm expects initial Phase Ib single ascending dose data to become available and notes the potential for an interim assessment that could inform a Phase IIa readout.
Attention in the ophthalmology community is also focused on Merck’s BRUNELLO trial results, which are scheduled for presentation on October 10, 2026 at the American Academy of Ophthalmology meeting. The BRUNELLO study comprises 984 patients, and Merck is expected to release topline results ahead of the conference.
Guggenheim underscores that a favorable BRUNELLO outcome demonstrating statistical significance or a numerical benefit in best corrected visual acuity improvement or reduction in central subfield thickness could be meaningful for the sector. The analyst notes that, to date, no alternative mechanism of action has shown non-inferiority to anti-VEGFs in pivotal trials for diabetic macular edema or wet age-related macular degeneration.